News articles about Cutera (NASDAQ:CUTR) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cutera earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 47.7256131770409 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Cutera (CUTR) traded up $2.85 during mid-day trading on Tuesday, hitting $53.45. The stock had a trading volume of 50,978 shares, compared to its average volume of 173,713. The firm has a market cap of $698.98, a PE ratio of 26.07, a PEG ratio of 1.09 and a beta of 0.51. Cutera has a fifty-two week low of $18.50 and a fifty-two week high of $54.25.
Cutera (NASDAQ:CUTR) last issued its quarterly earnings data on Wednesday, February 14th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.09. The business had revenue of $47.60 million during the quarter, compared to analysts’ expectations of $43.96 million. Cutera had a return on equity of 18.31% and a net margin of 19.80%. The company’s revenue for the quarter was up 25.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 EPS. research analysts forecast that Cutera will post 1.1 earnings per share for the current fiscal year.
In other news, insider James A. Reinstein sold 7,175 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $45.35, for a total value of $325,386.25. Following the completion of the transaction, the insider now owns 132,284 shares of the company’s stock, valued at approximately $5,999,079.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David B. Apfelberg sold 1,000 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $47.40, for a total value of $47,400.00. Following the completion of the transaction, the director now directly owns 8,259 shares of the company’s stock, valued at approximately $391,476.60. The disclosure for this sale can be found here. In the last three months, insiders sold 14,018 shares of company stock valued at $637,766. Insiders own 3.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Cutera (CUTR) Given Daily Coverage Optimism Score of 0.18” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://sportsperspectives.com/2018/03/13/cutera-cutr-given-daily-coverage-optimism-score-of-0-18.html.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.